<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04021342</url>
  </required_header>
  <id_info>
    <org_study_id>4240</org_study_id>
    <nct_id>NCT04021342</nct_id>
  </id_info>
  <brief_title>The Effect of Tart Cherry (Prunus Cerasus) Concentrate on Physiological and Cognitive Function</brief_title>
  <official_title>The Effect of Tart Cherry (Prunus Cerasus) Concentrate on Cardiometabolic Risk Factors, Exercise Capacity and Cognitive Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northumbria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cherry Marketing Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northumbria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double blind, counterbalanced, placebo controlled independent groups design to
      determine the effects of 3 month supplementation with tart cherry concentrate on indices of
      cardiometabolic health, exercise capacity and cognitive function. Following screening and
      recruitment, participants are familiarised with the testing equipment and procedures after
      which they will be randomly assigned to receive either Montmorency tart cherry concentrate
      (MC) or an isocaloric placebo (PLA), stratified by gender. The study is comprised of two
      experimental visits and outcome variables are assessed at baseline (before supplementation)
      and at 3 months (follow up; after supplementation).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The treatment drink (tart cherry concentrate) and placebo are matched for colour and packed in identical plastic containers. The assigned beverages are packed and given to the participants by an independent researcher not involved in the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial Stiffness</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Pulse wave velocity (m/s)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial Stiffness</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Augmentation index (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Flow mediated dilation (% change)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Indices of metabolic health</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>glucose (mmol/L) triglycerides (mmol/L) LDL cholesterol (mmol/L) HDL cholesterol (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Computerized cognitive function assessment percentage accuracy (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Computerized cognitive function assessment reaction time (m/s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Blood flow</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Oxygenated heamoglobin (Oxyhb)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Blood flow</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Deoxygenated heamoglobin (deoxyhb)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Estimated aerobic exercise capacity (VO2max) measured by a submaximal cycling test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body composition</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Fat mass (g) Lean mass (g)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body composition</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Fat percentage (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Body composition</measure>
    <time_frame>Change from baseline at 3 months</time_frame>
    <description>Android/gynoid ratio</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiometabolic Risk Factors</condition>
  <condition>Cognitive Function</condition>
  <condition>Exercise Capacity</condition>
  <arm_group>
    <arm_group_label>Montmorency tart cherry concentrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will consume 30 ml of Montmorency tart cherry concentrate (MC) concentrate (King Orchard farms, USA) twice daily, once in the morning and again in the evening. According to the manufacturer each 30 ml dose of MC is estimated to be equivalent to approximately 90 whole cherries (equating to ~180 cherries per day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isocaloric cherry flavoured placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The PLA is prepared by mixing by mixing unsweetened black cherry flavoured Kool-Aid (Kraft Foods, United States), dextrose, fructose with water to best match the calorie content of the MC concentrate. Additional lemon juice, for tartness, and artificial food colouring is added so the final product had a similar visual properties to the active comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Montmorency tart cherry concentrate</intervention_name>
    <description>Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)</description>
    <arm_group_label>Montmorency tart cherry concentrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo beverage matched for calorie content and visual properties of the cherry concentrate</description>
    <arm_group_label>Isocaloric cherry flavoured placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy individuals between the ages of 40-60 years

          -  consume on average ≤5 servings of fruits and vegetables per day

          -  additionally have ≥1 risk factor for type 2 diabetes

        Exclusion Criteria:

          -  not regularly taking medication (or stabilised ≥ 3 months, with no adverse symptoms)
             or antioxidant supplements

          -  history of cardiometabolic, gastointestinal disease or malabsorption syndromes

          -  stage 2 hypertension (SBP &gt;159 mm Hg or DBP &gt;99 mm Hg)

          -  individuals who report changes in dietary or physical activity patterns within 3
             months

          -  vegetarians, vegans or known eating disorders

          -  alcohol intake of more than 21 units per week

          -  BMI ≥40 kg/m2

          -  are pregnant or planning to become pregnant during the study, lactating, or initiating
             or changing a hormone replacement therapy regimen within 3 months of the start of the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Northumbria University</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE18ST</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel A C Kimble</last_name>
      <phone>0191 243 7018</phone>
      <email>rachel.kimble@northumbria.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Rachel A C Kimble</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Glyn Howatson, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2019</study_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tart cherry</keyword>
  <keyword>Montmorency cherries</keyword>
  <keyword>Prunus Cerasus</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

